Clinical Trials
7 trialsNCT05199584 2026-03-05
A Study Evaluating the Safety and Efficacy of ENV-101 (Taladegib) in Patients With Advanced Solid Tumors Harboring PTCH1 Loss of Function Mutations
Endeavor Biomedicines, Inc.
Phase 2 Completed
NCT02784795 2025-08-21
A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors
Eli Lilly and Company
Phase 1 Terminated
NCT02530437 2023-07-10
Taladegib, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Localized Esophageal or Gastroesophageal Junction Cancer
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT01226485 2019-09-13
A Study in Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT01919398 2019-09-11
A Study of LY2940680 in Japanese Participants With Advanced Cancers
Eli Lilly and Company
Phase 1 Completed
NCT01722292 2018-12-28
A Study of LY2940680 in Small Cell Lung Cancer
Eli Lilly and Company
Phase 1/2 Terminated
NCT01697514 2013-08-27
A Study of LY2940680 in Pediatric Medulloblastoma or Rhabdomyosarcoma
Eli Lilly and Company
Phase 1 Withdrawn